2010 AnnuAl REpoRT - Ciberdem

More documents

Recommendations

Info

The effects of metformin on cardiovascular risk factors in prepubertal children born small for gestational age without postnatal catch-up growth, currently treated with growth hormone Pfizer, PCP00046: 2009-2011 Principal Investigator: Lourdes Ibáñez Associate investigators: Paula Casano, Marta Díaz, Carme Valls, María Victoria Marcos Scientific collaborations within CIBERDEM Body fat amount and distribution in childhood determines predisposition to type 2 diabetes CHILDBODYFAT: 2009-2010 Coordinator: Lourdes Ibáñez CIBERDEM groups: L Ibáñez, X Correig, L Masana Clinical trials Endocrine-metabolic and body composition effects of metformin administration in prepubertal children with a low birthweight for gestational age, postnatal catch-up growth and risk markers for the metabolic syndrome. Phase II Instituto de Salud Carlos III, Fondo de Investigación Sanitaria, EC08/00160: 2008-2010 Name of the participants: Ibáñez L (PI), Casano P, Diaz M, Valls C, del Rio L, Marcos MV, Enríquez G, Sebastiani G, Hollenberg G, Fortea E and Cortés R (researchers) Cumulative gain in total and abdominal fat mass in prepubertal girls (age ~ 8 years) with a history of low birthweight and precocious pubarche, who were randomized to remain untreated (n=19; open circles) or to receive metformin (n=19; closed circles) for 4 yr, and who were then followed for 1 yr without intervention. Pubertal metformin treatment reduced fat gain not only through puberty, but also beyond puberty. Mean and 95% CI are shown. Difference in rate of change between subgroups significant by repeated-measures ANOVA. Image from: J Pediatr, 2010. Effects of the addition of metformin to growth hormone therapy on cardiovascular risk factors in prepubertal short children born small for gestational age. Phase II Instituto de Salud Carlos III, Fondo de Investigación Sanitaria, EC10/0031: 2010-2012 Name of the participants: Casano P (PI), Ibáñez L, Diaz M and Sebastiani G (researchers) Ethynil-estradiol-cyproterone acetate versus low-dose pioglitazone + flutamide + metformin in adolescents with hyperinsulinemic ovarian hyperandrogenism: Effects on parameters of chronic inflammation and on risk factors of type 2 diabetes and cardiovascular risk. Phase II Instituto de Salud Carlos III, Fondo de Investigación Sanitaria, PI09/90444: 2009-2011 Name of the participants: Ibáñez L (PI), Diaz M, Casano P, López-Bermejo A, Marcos MV, Mir I, Moran E and Salvador C (researchers) Comparative study of subcutaneous insulin pump, glargine insulin and NPH in diabetic children aged 0-6 yr. Phase II Instituto de Salud Carlos III, Fondo de Investigación Sanitaria, EC07/90900: 2009-2011 Name of the participants: Torres M (PI), Casano P, Díaz R, Jaramillo A, Anguita C, Gómez A and Marin S (researchers) Changes over 4 months (mean ± SEM) in total fat mass (by absorptiometry), abdominal (abd) subcutaneous (subc) fat (by magnetic resonance imaging), high-molecular-weight adiponectin (HMW adipo) and follistatin in short SGA children, before (N=18; open bars) and during (N=35; shaded bars) growth hormone (GH) treatment. *p
Clinical practice guidelines Insulin resistance in children: consensus, perspective, and future directions Journal of Clinical Endocrinology & Metabolism, 95, 5189- 5198 (2010) Institution: Consensus Meeting (ESPE-LWPES-ISPAD- APPES-APEG-SLEP-JSPE) Authors: Levy-Marchal C, Arslanian S, Cutfield W, Sinaiko A, Druet C, Marcovecchio ML, Chiarelli F; ESPE-LWPES-ISPAD- APPES-APEG-SLEP-JSPE; Insulin Resistance in Children Consensus Conference Group Patents International patent Composition comprising an androgen receptor blocker and an insulin sensitizing agent and use thereof for treatment of polycystic ovary syndrome Patent application number: PCT/BE 02/00052 Inventors: Francis de Zegher, Lourdes Ibáñez University of Leuven and University of Barcelona (2010) Awards Accésit Premio Merck-Serono de Investigación de la Sociedad Española de Endocrinología Pediátrica. Original: Abdominal fat partitioning and high-molecular-weight adiponectin in short children born small-for-gestational-age. Hospital Sant Joan de Déu (2010) Awardees: Ibáñez L, López-Bermejo A, Diaz M, Marcos MV, Casano P, de Zegher F ■ 68 CibeRdem
Page 1 and 2:
2010 Annual Report CIBERDEM Centro
Page 4 and 5:
Letter from the Scientific Director
Page 6 and 7:
Contents Prologue Research results
Page 8 and 9:
Research results Publications In 20
Page 10 and 11:
Project management Introduction The
Page 12 and 13:
Training programme Introduction The
Page 14 and 15:
Outreach activities CIBERDEM Fundra
Page 16 and 17:
More about CIBERDEM The Centro de I
Page 18 and 19: Human Resources In 2010, CIBERDEM h
Page 20 and 21: Transversal projects Di@bet.es Stud
Page 22 and 23: Di@bet.es Study Introduction Attemp
Page 24 and 25: CIBERDEM Projects Introduction CIBE
Page 26 and 27: girls (girls born small for gestati
Page 28 and 29: Biobank Introduction and objectives
Page 30 and 31: Metabolomics Platform Introduction
Page 33 and 34: Area 1 Insulin signalling and resis
Page 35 and 36: Diabetes and cardiovascular Faculta
Page 37 and 38: Metabolomics Platform Universitat R
Page 39 and 40: Obesity, inflammation and insulin r
Page 41 and 42: Mechanisms of control of glucose an
Page 43 and 44: Metabolic engineering and diabetes
Page 45 and 46: Molecular mechanisms of insulin res
Page 47 and 48: Molecular characteristics, and acti
Page 49 and 50: Heterogenic and polygenic diseases.
Page 51: Principal Investigator: Antonio Zor
Page 54 and 55: The research activity of this area
Page 56 and 57: The cationic cluster of group IVA p
Page 58 and 59: agent that affects the enterohepati
Page 60 and 61: Dyslipidaemia, inflammation and end
Page 62 and 63: Daño orgánico en la diabetes mell
Page 64 and 65: Proteomic analysis of plasma in the
Page 66 and 67: Prenatal growth restriction and sub
Page 70 and 71: Lipids and Arteriosclerosis Researc
Page 72 and 73: Review Pitavastatin - from clinical
Page 74 and 75: Diabetobe Hospital Clínico San Car
Page 76 and 77: Scientific collaborations within CI
Page 78 and 79: Atherosclerosis, 209, 201-205 (2010
Page 80 and 81: Solvay, SA: 2008-2010 Principal Inv
Page 82 and 83: Endocrinology and Nutrition Service
Page 84 and 85: Prevención de la Diabetes mellitus
Page 86 and 87: Pharmacological targets in inflamma
Page 88 and 89: Diabetes and Metabolic Associated D
Page 90 and 91: Autonomous Community project Grup d
Page 92 and 93: Area 3 of CIBERDEM comprises thirte
Page 94 and 95: Escrivá F, Alvarez C J Mol Endocri
Page 96 and 97: Am J Physiol Endocrinol Metab, 298,
Page 98 and 99: Transgenic animal models and gene t
Page 100 and 101: Ayuso E, Mingozzi F, Bosch F Curr G
Page 102 and 103: Laboratory of Molecular Endocrinolo
Page 104 and 105: Hospital de Cruces Diabetes Researc
Page 106 and 107: Research grants International proje
Page 108 and 109: Proinsulin and tyrosine hydroxilase
Page 110 and 111: Genomic programming of beta cells I
Page 112 and 113: Diabetes and obesity: biopathology
Page 114 and 115: Utilidad de la ecografía arterial
Page 116 and 117: Islet cell and stem cell physiology
Page 118 and 119:
in diabetic patients with chronic c
Page 120 and 121:
Liraglutide versus sitagliptin for
Page 122 and 123:
Unit of Cell Physiology and Nutriti
Page 124 and 125:
National projects Efectos a corto y
Page 126 and 127:
Altirriba J, Gasa R, Casas S, Ramí
Page 128 and 129:
Transcriptional mechanisms of pancr
Page 131 and 132:
Epilogue
Page 133 and 134:
Keyword index* Beta-cell signal tra
Page 135 and 136:
Association of selected ABC gene fa
Page 137 and 138:
Leiter LA, Levitt NS, Mareev V, Mar
Page 139 and 140:
Low body adiposity and high leptine
Page 141 and 142:
Alvaro A, Rosales R, Masana L, Vall
Page 143 and 144:
The apolipoprotein A5 (APOA5) gene
Page 145 and 146:
www.ciberdem.org/annualreport CIBER
show all

2010 AnnuAl REpoRT - Ciberdem

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?